December 03, 2019“ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug” – Proactive Investors Read More November 29, 2019Drug deal revives ImmuPharma. The Times – 29 November 2019 Read More November 29, 2019SMALL CAP MOVERS: ImmuPharma nearly trebles in value as US deal resurrects flagship lupus drug Read More November 28, 2019ImmuPharma Soars On Avion Lupus Deal – Validates Management Faith In Lupuzor™. Scrip | Informa Pharma Intelligence – 28 November 2019 Read More September 30, 2019Immupharma steadfast in belief Lupuzor™ has commercial merit – Proactive Investors Read More August 12, 2019ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor™ – Proactive Investors Read More June 28, 2019ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug – Proactive Investors Read More November 07, 2018Chairman Tim McCarthy explains how a new, extensive programme and additional research into the drug’s use in treating other auto-immune diseases could still see it achieve its ‘blockbuster potential – Value The Markets Read More June 04, 2018Benefits of Lupuzor™ Add-on Seen in European Lupus Patients – Lupus News Today Read More April 24, 2018Add-on Lupuzor Fails Primary Goal but Shows Some Positive Results in Phase 3 Trial for SLE Read More April 24, 2018ImmuPharma chairman and chief executive upbeat on Lupuzor™; industry interest remains strong – 23 April 2018 Read More February 05, 2018Small Company Share Watch – Feb 2018 Read More 1234
December 03, 2019“ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug” – Proactive Investors Read More
November 29, 2019SMALL CAP MOVERS: ImmuPharma nearly trebles in value as US deal resurrects flagship lupus drug Read More
November 28, 2019ImmuPharma Soars On Avion Lupus Deal – Validates Management Faith In Lupuzor™. Scrip | Informa Pharma Intelligence – 28 November 2019 Read More
September 30, 2019Immupharma steadfast in belief Lupuzor™ has commercial merit – Proactive Investors Read More
August 12, 2019ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor™ – Proactive Investors Read More
June 28, 2019ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug – Proactive Investors Read More
November 07, 2018Chairman Tim McCarthy explains how a new, extensive programme and additional research into the drug’s use in treating other auto-immune diseases could still see it achieve its ‘blockbuster potential – Value The Markets Read More
June 04, 2018Benefits of Lupuzor™ Add-on Seen in European Lupus Patients – Lupus News Today Read More
April 24, 2018Add-on Lupuzor Fails Primary Goal but Shows Some Positive Results in Phase 3 Trial for SLE Read More
April 24, 2018ImmuPharma chairman and chief executive upbeat on Lupuzor™; industry interest remains strong – 23 April 2018 Read More
